



February 9, 2023

Name of Company: Meiji Holdings Co., Ltd.
Name of Representative: Kazuo Kawamura, CEO, President and Representative Director
Code Number: 2269, Prime Market, Tokyo Stock Exchange

Notice concerning Revisions to Financial Forecasts for the Fiscal Year Ending March 31, 2023

Meiji Holdings Co., Ltd. today announces that we revised our earnings forecasts for the fiscal year ending March 31, 2023 (FY2022), announced on November 8, 2022, as described below.

1. Revised Forecasts of Consolidated Financial Results for the Fiscal Year Ending March 31, 2023 (April 1, 2022 to March 31, 2023)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Profit per share
	millions of yen	millions of yen	millions of yen	millions of yen	yen
Previous forecasts (A)	1,052,500	83,500	85,500	60,000	426.00
Revised forecasts (B)	1,058,000	77,500	76,000	62,000	440.89
Change (B-A)	5,500	-6,000	-9,500	2,000	
Percentage of change	0.5	-7.2	-11.1	3.3	
(Reference) Results for the fiscal year ended March 31, 2022	1,013,092	92,922	93,985	87,497	607.24

2. Reasons for Revisions

Net sales will be largely unchanged from our previous forecast but we forecast operating profit to decrease by JPY 6 billion compared to our previous forecast. While the pharmaceutical segment as a whole is progressing according to plans, the food segment is experiencing higher-than-expected increases in energy costs. While we strengthened marketing activities to minimize the impact of price hikes on sales volume, it is taking time for the effect to show for yogurt and certain other products.

We forecast ordinary profit to decrease by JPY 9.5 billion compared to our previous forecast. In addition to projections that food segment operating profit will fall below our previous forecast, we forecast lump-sum amortization of goodwill related to an equity method affiliate.

We are forecasting profit attributable to owners of parent to increase by JPY 2 billion compared to our previous forecast. While we will record business restructuring expenses in the pharmaceutical

segment as extraordinary losses in addition to the impact of decreased profit in the food segment, we expect to record approximately JPY 10.9 billion in gain on sale of non-current assets related to the former Pharmaceutical Research Center (Yokohama) as extraordinary income.

* Financial forecasts indicated in these materials are based on information currently available to the Company and certain assumptions deemed to be reasonable. Actual financial results may change due to various factors.

#####